Status:
RECRUITING
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Lead Sponsor:
Ruijin Hospital
Conditions:
PET / CT
Lung Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which doe...
Eligibility Criteria
Inclusion
- Lung cancer patients who develope lesion enlargement and/or new lesions after treatment with immune checkpoint inhibitors;
- Pseudoprogression cannot be ruled out in clinical practice;
- Lung cancer confirmed by pathology or cytology, regardless of pathological type;
- Fully-informed written consent obtained from patients;
- Patient ability to comply with protocol requirements;
- Age 18-75 years;
- Life expectancy of at least 6 months.
Exclusion
- Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc;
- Intestinal perforation, complete intestinal obstruction;
- Active phase of hepatitis B；
- Pregnant women and women who are potentially pregnant, as well as nursing mothers;
- Patients with poor compliance.
Key Trial Info
Start Date :
June 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06608160
Start Date
June 20 2024
End Date
December 31 2025
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200000